We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-10.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.15B
AUM Growth
-$1.56B
Cap. Flow
-$673M
Cap. Flow %
-16.21%
Top 10 Hldgs %
47.21%
Holding
133
New
21
Increased
21
Reduced
31
Closed
23

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$45.8M
3
IMTX icon
Immatics
IMTX
+$39.5M
4
CTNM
Contineum Therapeutics
CTNM
+$25.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$19M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$149M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$146M
3
MDT icon
Medtronic
MDT
+$77M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$47.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$5.45B
$22.7M 0.55%
583,256
-308,952
-35% -$12.3M
OCUL icon
52
Ocular Therapeutix
OCUL
$2.24B
$22.7M 0.55%
3,324,468
– –
PEPG icon
53
PepGen
PEPG
$200M
$22.5M 0.54%
1,410,438
– –
VRDN icon
54
Viridian Therapeutics
VRDN
$2.47B
$21.2M 0.51%
1,631,828
-2,025,271
-55% -$28M
OBIO icon
55
Orchestra BioMed
OBIO
$363M
$20.7M 0.5%
2,545,881
– –
MRUS
56
DELISTED
Merus
MRUS
$17.8M 0.43%
+300,000
New +$14.5M
RAPP
57
Rapport Therapeutics
RAPP
$2.05B
$17.4M 0.42%
+748,183
New +$17.3M
TYRA icon
58
Tyra Biosciences
TYRA
$1.52B
$16.1M 0.39%
1,007,367
+338,208
+51% +$5.82M
INBX icon
59
Inhibrx
INBX
$1.55B
$15.1M 0.36%
+1,064,026
New +$16.6M
ARQT icon
60
Arcutis Biotherapeutics
ARQT
$2.96B
$14.5M 0.35%
1,558,500
+808,500
+108% +$7.31M
LONA
61
LeonaBio Inc
LONA
$68.2M
$14.3M 0.34%
540,296
– –
ZYME icon
62
Zymeworks
ZYME
$1.86B
$14.2M 0.34%
1,667,711
+592,904
+55% +$5.28M
CGEM icon
63
Cullinan Oncology
CGEM
$1.32B
$13.1M 0.32%
+749,916
New +$16M
PRCT icon
64
Procept Biorobotics
PRCT
$1.11B
$12.9M 0.31%
210,659
– –
INSM icon
65
Insmed
INSM
$26.2B
$12.1M 0.29%
+180,000
New +$6.98M
BCYC
66
Bicycle Therapeutics
BCYC
$257M
$11.6M 0.28%
+572,000
New +$12.9M
ICLR icon
67
Icon
ICLR
$13.3B
$9.8M 0.24%
+31,250
New +$9.79M
TEM
68
Tempus AI
TEM
$12.5B
$9.63M 0.23%
+275,000
New +$8.43M
AVBP icon
69
ArriVent BioPharma
AVBP
$1.38B
$7.7M 0.19%
415,000
– –
ENGN icon
70
enGene Therapeutics
ENGN
$127M
$7.54M 0.18%
800,000
-198,888
-20% -$2.55M
SPRY icon
71
ARS Pharmaceuticals
SPRY
$423M
$7.38M 0.18%
867,319
– –
ARGX icon
72
argenx
ARGX
$61.3B
$6.71M 0.16%
+15,600
New +$5.97M
ALLO icon
73
Allogene Therapeutics
ALLO
$594M
$6.35M 0.15%
+2,725,000
New +$8.04M
VERU icon
74
Veru
VERU
$39.9M
$5.94M 0.14%
706,328
+147,858
+26% +$1.71M
KALV
75
DELISTED
KalVista Pharmaceuticals
KALV
$5.89M 0.14%
500,000
– –
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Perceptive Advisors held 133 positions worth $4.15B, down 27% from $5.72B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors withdrew a net $673M in Q2 2024, closing 23 positions and reducing 31 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Contineum Therapeutics worth $27.6M.

  • Perceptive Advisors's largest Q2 2024 buy was Contineum Therapeutics: 1,566,668 shares worth $27.6M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q2 2024, an estimated $71.4M increase.
  • Perceptive Advisors's biggest Q2 2024 reduction was Medtronic, cutting an estimated $77M.
  • Perceptive Advisors fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $149M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $4.15B portfolio in Q2 2024.
  • Perceptive Advisors opened 21 new positions and closed 23 in Q2 2024.
  • Perceptive Advisors's portfolio value fell 27% quarter-over-quarter to $4.15B.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.